[HTML][HTML] Antisense oligonucleotides: an emerging area in drug discovery and development

K Dhuri, C Bechtold, E Quijano, H Pham… - Journal of clinical …, 2020 - mdpi.com
K Dhuri, C Bechtold, E Quijano, H Pham, A Gupta, A Vikram, R Bahal
Journal of clinical medicine, 2020mdpi.com
Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and
modulate protein expression through several different mechanisms. The ASO field is an
emerging area of drug development that targets the disease source at the RNA level and
offers a promising alternative to therapies targeting downstream processes. To translate
ASO-based therapies into a clinical success, it is crucial to overcome the challenges
associated with off-target side effects and insufficient biological activity. In this regard …
Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and modulate protein expression through several different mechanisms. The ASO field is an emerging area of drug development that targets the disease source at the RNA level and offers a promising alternative to therapies targeting downstream processes. To translate ASO-based therapies into a clinical success, it is crucial to overcome the challenges associated with off-target side effects and insufficient biological activity. In this regard, several chemical modifications and diverse delivery strategies have been explored. In this review, we systematically discuss the chemical modifications, mechanism of action, and optimized delivery strategies of several different classes of ASOs. Further, we highlight the recent advances made in development of ASO-based drugs with a focus on drugs that are approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for clinical applications. We also discuss various promising ASO-based drug candidates in the clinical trials, and the outstanding opportunity of emerging microRNA as a viable therapeutic target for future ASO-based therapies.
MDPI